Evelo Biosciences

Evelo Biosciences

Evelo Biosciences launched in 2015 within Flagship Pioneering's venture-creation engine, founded by CEO Simba Gill and CSO Balkrishan Gill. The wealth origin is corporate venture capital from Flagship, not a family's operating business. The firm sought to develop orally delivered monoclonal microbials — single strains of bacteria designed to engage the small intestine's immune axis and produce systemic therapeutic effects against cancer, psoriasis, and atopic dermatitis. It became a public company via a reverse merger in 2018 (per the firm's official communications). The company's strategy centered on a unique drug-discovery platform that matched specific gut-resident immune cells to disease biology. Its pipeline included EDP1815 for psoriasis and atopic dermatitis, EDP1908 for oncology, and EDP1867 for undisclosed inflammatory conditions. The geographic focus was clinical-trial execution and manufacturing in the United States and the United Kingdom, where it established research partnerships and trial sites. Evelo was a lean biotech operation with no disclosed total professionals. It maintained its research headquarters in Cambridge, Massachusetts, and operated as a single-entity public company without adjacent philanthropic foundations, family-office wealth management, or real-asset arms. The firm's structure was a conventional Delaware C-corporation with institutional venture-capital backers including Flagship Pioneering and Google Ventures (per public record). In November 2023, after multiple clinical-trial failures, Evelo announced it was exploring strategic alternatives and winding down operations, ceasing to be a going concern (per the firm's official communications). The firm's structural differentiator was its bet on monoclonal microbials as a distinct new drug modality, fully decoupled from the complex fecal-transplant or consortia-based microbiome approaches that dominated the field. This focus on a single defined bacterial strain — a "drug in a capsule" — was intended to create pharmaceutical-grade consistency, scalability, and IP protection that mixed-strain competitors could not match.